What Ennocure Medtech does

Ennocure Medtech (legally ENNOCURE GmbH) is an Austrian medical technology company developing the Ennocure Smart Patch, a bioelectronic wound dressing that combines microcurrent stimulation with embedded continuous-monitoring sensors for the treatment of chronic wounds. The product architecture pairs a silicone foam dressing with electronics that deliver controlled electric fields intended to orchestrate keratinocyte and fibroblast migration and disrupt bacterial biofilms, while integrated sensors track electrical resistance and ionic activity 24/7 to provide non-invasive insight into healing progression. The system is sold as a unified offering: the Smart Patch device, a patient-facing mobile application, and a clinical platform with AI-driven alerts that flag deviations from expected healing patterns for remote clinical oversight.

The company targets two primary segments: chronic wound patients—specifically those with diabetic foot ulcers and venous leg ulcers whose natural 'current of injury' is exhausted and who require continuous at-home treatment and monitoring—and the healthcare providers who oversee their care between clinic visits. The go-to-market approach is direct and sales-led, relying on a contact form on ennocure.com to capture inquiries from patients and clinicians rather than through disclosed distribution partners, payer contracts, or named reference customers. No pricing, reimbursement strategy, or distributor network has been disclosed in the source material.

Ennocure is pre-revenue and the Smart Patch is explicitly described as under development and not approved for clinical use. The company is privately held as an Austrian GmbH, has a nine-person international team led by Dr. Manuela Hod (CEO) and Dr. Christoph Huber (COO), and has not publicly disclosed any funding rounds, partnerships, regulatory submissions, certifications, or named customers. Its registered office is in Klagenfurt am Wörthersee, Austria, and it maintains an Israeli phone contact line.

Name

Ennocure Medtech

Legal name

ENNOCURE GmbH

Website

https://ennocure.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Ennocure Medtech is an Austrian medtech company developing a bioelectronic smart wound patch that combines microcurrent therapy with continuous AI-driven sensor monitoring, targeting chronic wound patients and their healthcare providers.

Ownership category

akta.pro rank

Product category

Smart Wound Care Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Care & Ulcer Management (HLAKACAN)

Keywords

• Smart wound care
• Microcurrent therapy
• Chronic wound management
• Bioelectronic medicine
• Remote patient monitoring

Headquarters

HQ city

Klagenfurt am Wörthersee

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Smart Wound Patch Device: Sale of the Ennocure Smart Patch device which delivers microcurrent treatment with integrated monitoring capabilities. The product combines hardware (patch with embedded electronics), software (patient app and clinical platform), and consumable elements (wound dressing). Pre-revenue as product is under development and not yet approved for clinical use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Ennocure develops the Ennocure Smart Patch, a bioelectronic wound dressing that combines silicone foam dressing materials with embedded microcurrent technology and integrated sensors. The system delivers controlled electrical stimulation to reactivate stalled healing in chronic wounds while continuously monitoring wound conditions 24/7, with data accessible to patients via a mobile app and to clinicians via a clinical platform featuring AI-driven alerts.

Product overview

Ennocure offers a unified smart wound care system combining the Ennocure Smart Patch (a microcurrent-enabled silicone foam dressing with embedded sensors) with the Patient App and Clinical Platform. The Smart Patch delivers continuous electrical stimulation to reactivates stalled healing in chronic wounds while sensors monitor wound conditions 24/7. The Patient App provides real-time data to patients at home, while the Clinical Platform enables healthcare providers to remotely oversee patients and receive AI-driven alerts for timely interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• Ennocure Smart Patch An integrated smart wound care system designed for chronic wound patients (such as those with diabetic foot ulcers and venous leg ulcers) for at-home use. The system combines a silicone foam wound dressing with embedded microcurrent technology, integrated sensors for continuous 24/7 monitoring of electrical resistance and ionic activity, a patient-facing mobile app for real-time wound tracking, and a clinical platform providing healthcare providers with AI-driven alerts and remote oversight capabilities.

Quantifiable outcome

• Over $90B in annual costs driven by chronic wounds globally
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Direct peers

• MolecuLight: Canadian commercial-stage company selling handheld fluorescence imaging devices (i:X, DX) that detect bacterial load in chronic wounds in real time. Most directly comparable as a digital wound-care technology player bringing objective, point-of-care data to wound assessment — Ennocure's continuous sensor approach competes in the same 'objective wound data' category.
• Swift Medical: Canadian digital health company offering a smartphone-based AI wound imaging and measurement platform used by home-health agencies and wound clinics. Comparable as a connected wound-care software play; Swift focuses on imaging while Ennocure focuses on embedded biosensors, but both sell into remote wound monitoring workflows.
• Spectral AI: US-listed (MDIT on Nasdaq prior to planned uplisting) developer of the DeepView AI wound-healing assessment platform, combining multispectral imaging with predictive AI to forecast burn and chronic-wound healing. Closest publicly-traded peer in AI-driven wound assessment; targets similar clinical decision-support use cases Ennocure's Clinical Platform addresses.

Broad incumbents

• Coloplast: Danish medtech serving wound care (Biatain, Comfeel) and ostomy customers globally. Comparable as a premium wound-dressing supplier with similar end users; Ennocure's connected platform is the key point of product divergence.
• Solventum (3M Health Care spinoff): Spun off from 3M in 2024, Solventum retains the legacy 3M wound-care franchise including V.A.C. NPWT systems and advanced dressings. It is the most entrenched NPWT competitor and the incumbent most likely to bundle monitoring/AI features into existing V.A.C. platforms.
• Smith & Nephew: Global medical-device leader with a substantial Advanced Wound Management portfolio (ALLEVYN dressings, PICO single-use NPWT, VERSAJET, RENASYS). Ennocure competes for the same chronic-wound budget at hospitals, wound clinics, and home-care, though Smith & Nephew does not currently offer a connected microcurrent dressing.
• Convatec: UK-listed medtech with a dedicated Advanced Wound Care franchise (AQUACEL, FoamLite, InnovaMatrix). Targets the same diabetic foot ulcer / venous leg ulcer patient population and overlapping clinician call points; competing primarily on dressing technology rather than connected therapeutics.
• Mölnlycke Health Care: Swedish private company and one of the world's largest advanced wound-care suppliers (Mepilex Border, Mepitel, Exufiber). Comparable as a high-end silicone-foam dressing provider targeting the same chronic-wound prescribers; Mölnlycke lacks an integrated electrotherapy/monitoring platform today.

Emerging players

• Organogenesis: US-listed regenerative medicine company (Apligraf, Dermagraft, PuraPly) selling skin substitutes and advanced biologics for chronic wounds. Comparable as a non-dressing advanced therapy targeting the same stalled-healing indications (DFU, VLU), though its mechanism (cellular matrices) differs from Ennocure's microcurrent approach.
• MiMedx: US-listed developer of placental tissue allografts (EpiFix, AmnioFix) used in chronic wound and surgical recovery. Comparable as an emerging advanced-therapy wound-care company targeting diabetic foot ulcers and venous leg ulcers with a mechanism different from microcurrent but competing for the same reimbursement and prescriber mindshare.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ennocure

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ennocure Medtech